ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBIO
101
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $410K | 0.08% |
246,936
+231,036
| +1,453% | +$384K |
|
102
CG Oncology
CGON
$2.19B
| $406K | 0.08% |
12,850
+10,800
| +527% | +$341K |
|
103
RenovoRx
RNXT
$45.8M
| $401K | 0.08% |
+355,240
| New | +$401K |
|
104
TripAdvisor
TRIP
$2B
| $392K | 0.07% |
+22,000
| New | +$392K |
|
105
Movano
MOVE
$7.39M
| $387K | 0.07% |
+1,407,000
| New | +$387K |
|
106
Wave Life Sciences
WVE
$1.27B
| $382K | 0.07% |
76,651
+46,651
| +156% | +$233K |
|
107
Geron
GERN
$893M
| $382K | 0.07% |
90,000
+88,705
| +6,850% | +$376K |
|
108
Zai Lab
ZLAB
$3.48B
| $381K | 0.07% |
22,000
| – | – |
|
|
ABVX
109
Abivax
ABVX
$6.32B
| $357K | 0.07% |
27,000
+12,000
| +80% | +$159K |
|
110
Abbott
ABT
$230B
| $343K | 0.06% |
3,300
+1,900
| +136% | +$197K |
|
111
VYNE Therapeutics
VYNE
$8.09M
| $337K | 0.06% |
171,217
+61,126
| +56% | +$120K |
|
112
Option Care Health
OPCH
$4.7B
| $332K | 0.06% |
12,000
+5,000
| +71% | +$139K |
|
113
Janux Therapeutics
JANX
$1.38B
| $331K | 0.06% |
7,891
-6,109
| -44% | -$256K |
|
|
GRAL
114
GRAIL, Inc. Common Stock
GRAL
$1.17B
| $329K | 0.06% |
+21,401
| New | +$329K |
|
115
Oak Woods Acquisition Corp
OAKU
| $326K | 0.06% |
30,000
| – | – |
|
|
ORKA
116
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $324K | 0.06% |
+84,676
| New | +$324K |
|
|
JVSAU
117
DELISTED
JVSPAC Acquisition Corp. Unit
JVSAU
| $313K | 0.06% |
30,000
| – | – |
|
118
Mineralys Therapeutics
MLYS
$1.94B
| $297K | 0.06% |
25,366
+1,366
| +6% | +$16K |
|
119
West Pharmaceutical
WST
$17.9B
| $293K | 0.06% |
890
-610
| -41% | -$201K |
|
|
EDR
120
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $287K | 0.05% |
10,615
-144,635
| -93% | -$3.91M |
|
121
Tourmaline Bio
TRML
$645M
| $271K | 0.05% |
21,060
+9,500
| +82% | +$122K |
|
122
Milestone Pharmaceuticals
MIST
$151M
| $267K | 0.05% |
202,460
| – | – |
|
123
MKS Inc. Common Stock
MKSI
$6.73B
| $261K | 0.05% |
+2,000
| New | +$261K |
|
|
IROHU
124
Iron Horse Acquisitions Corp. Unit
IROHU
$62.2M
| $257K | 0.05% |
25,000
| – | – |
|
125
Korro Bio
KRRO
$245M
| $244K | 0.05% |
+7,210
| New | +$244K |
|